Notification of change in holdings according to Chapter 9, Section 10 of the Finnish Securities Market Act
Revenio Group Corporation | Stock Exchange Release | May 29, 2026 at 16:00:00 EEST
Revenio Group Corporation has received the following notification pursuant to Chapter 9, section 5 of the Securities Markets Act (”SMA”), according to which Caravelle Capital SAS’s voting rights in Revenio Group exceeded 5 percent on May 29, 2026.
Total position of Caravelle Capital SAS according to the notification:
| % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both in % | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 5.22% | 5.22% | 29,166,913 | |
| Position of previous notification (if applicable) |
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights:
| Class/type of shares, ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009010912 | 1,522,754 | - | 5.22% | - |
| SUBTOTAL A | 1,522,754 | 5.22% | ||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
For further information, please contact
CEO Jouni Toijala, tel. +358 50 484 0085
jouni.toijala@revenio.fi
Distribution
Nasdaq Helsinki Ltd
Financial Supervisory Authority (FIN-FSA)
Main media
www.reveniogroup.fi/en
Revenio Group in brief
Revenio is a leading turnkey solutions provider in the global eye care market. The group offers fast, user-friendly, and reliable tools for diagnosing a wide variety of eye diseases. Revenio’s solutions include e.g. tonometers, fundus imaging devices, optical coherence tomography (OCT), perimeters, multimodal devices, refraction systems, and software solutions under iCare and Visionix.
In May 2026, Revenio joined forces with Visionix, creating the most innovative, creative and comprehensive entity serving eye care professionals across optometry, optical retail and ophthalmology. In 2025, the Group’s net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.